Platelet mass cytometry reveals dysregulation of prothrombotic pathways in essential thrombocythemia

Veronika Dill Kilian Kirmes Jiaying Han Melissa Klug Marc Rosenbaum Giacomo Viggiani Moritz von Scheidt Markus List Peter Herhaus Jürgen Ruland Florian Bassermann Karl-Ludwig Laugwitz Katharina S. Götze Philipp J. Jost Stefanie Jilg Conor J. Bloxham Philip W.J. Raake Isabell Bernlochner Dario Bongiovanni 1 Department of Internal Medicine III,School of Medicine,University Hospital rechts der Isar,Munich,Germany2 German Cancer Consortium (DKTK),Partner site Munich,Munich,Germany3 German Cancer Research Center (DKFZ),Heidelberg,Germany4 Department of Internal Medicine I,School of Medicine,University Hospital rechts der Isar,Munich,Germany5 German Center for Cardiovascular Research (DZHK),Partner site Munich Heart Alliance,Munich,Germany6 Experimental Bioinformatics,TUM School of Life Sciences Weihenstephan,Technical University of Munich,Munich,Germany7 School of Medicine,Institute of Clinical Chemistry and Pathobiochemistry,Technical University of Munich,Munich,Germany8 TranslaTUM,Center for Translational Cancer Research,Technical University of Munich,Munich,Germany9 Department of Cardiology,Deutsches Herzzentrum München,Technical University of Munich,Munich,Germany10 Clinical Department of Oncology,Medical University of Graz,Graz,Austria11 Onkologie Erding,Erding,Germany12 Department of Internal Medicine I,Cardiology,University Hospital Augsburg,University of Augsburg,Augsburg,Germany13 Department of Cardiovascular Medicine,Humanitas Clinical and Research Center IRCCS and Humanitas University,Rozzano,Milan,Italy

DOI: https://doi.org/10.1080/09537104.2024.2358244

2024-06-08

Platelets

Abstract:Thromboembolic events are common in patients with essential thrombocythemia (ET). However, the pathophysiological mechanisms underlying the increased thrombotic risk remain to be determined. Here, we perform the first phenotypical characterization of platelet expression using single-cell mass cytometry in six ET patients and six age- and sex-matched healthy individuals. A large panel of 18 transmembrane regulators of platelet function and activation were analyzed, at baseline and after ex-vivo stimulation with thrombin receptor-activating peptide (TRAP). We detected a significant overexpression of the activation marker CD62P (p-Selectin) ( p = .049) and the collagen receptor GPVI ( p = .044) in non-stimulated ET platelets. In contrast, ET platelets had a lower expression of the integrin subunits of the fibrinogen receptor GPIIb/IIIa CD41 ( p = .036) and CD61 ( p = .044) and of the von Willebrand factor receptor CD42b ( p = .044). Using the FlowSOM algorithm, we identified 2 subclusters of ET platelets with a prothrombotic expression profile, one of them (cluster 3) significantly overrepresented in ET (22.13% of the total platelets in ET, 2.94% in controls, p = .035). Platelet counts were significantly increased in ET compared to controls ( p = .0123). In ET, MPV inversely correlated with platelet count ( r =-0.96). These data highlight the prothrombotic phenotype of ET and postulate GPVI as a potential target to prevent thrombosis in these patients. Essential thrombocythemia (ET) is a rare disease characterized by an increased number of platelets in the blood. As a complication, many of these patients develop a blood clot, which can be life-threatening. So far, the reason behind the higher risk of blood clots is unclear. In this study, we analyzed platelet surface markers that play a critical role in platelet function and platelet activation using a modern technology called mass cytometry. For this purpose, blood samples from 6 patients with ET and 6 healthy control individuals were analyzed. We found significant differences between ET platelets and healthy platelets. ET platelets had higher expression levels of p-Selectin (CD62P), a key marker of platelet activation, and of the collagen receptor GPVI, which is important for clot formation. These results may be driven by a specific platelet subcluster overrepresented in ET. Other surface markers, such as the fibrinogen receptor GPIIb/IIIa CD41, CD61, and the von Willebrand factor receptor CD42b, were lower expressed in ET platelets. When ET platelets were treated with the clotting factor thrombin (thrombin receptor-activating peptide, TRAP), we found a differential response in platelet activation compared to healthy platelets. In conclusion, our results show an increased activation and clotting potential of ET platelets. The platelet surface protein GPVI may be a potential drug target to prevent abnormal blood clotting in ET patients.

cell biology,hematology

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve

This paper aims to explore the mechanisms of platelet dysfunction in patients with Essential Thrombocythemia (ET). ET is a rare blood disorder characterized by an increased number of platelets in the blood. Many ET patients experience thrombotic events, which can be fatal. However, the specific pathophysiological mechanisms that increase the risk of thrombosis in these patients are not yet clear.

To investigate this issue, the authors used mass cytometry by time of flight (CyTOF) to perform phenotypic analysis of platelet surface markers in ET patients and compared them with healthy controls. Through this method, the authors hope to reveal the differences in expression of platelets in ET patients in both resting and activated states, thereby identifying potential mechanisms that may lead to thrombosis.

### Main Findings

1. **Differential Expression of Platelet Surface Markers**:
- In the unstimulated state, platelets from ET patients exhibited higher expression of activation marker CD62P (p-Selectin) and collagen receptor GPVI.
- Conversely, platelets from ET patients showed lower expression of fibrinogen receptor GPIIb/IIIa (CD41 and CD61) and von Willebrand factor receptor CD42b in the unstimulated state.

2. **Heterogeneity of Platelet Subpopulations**:
- Using the FlowSOM algorithm, the authors identified 8 platelet subpopulations with similar expression profiles. Among these, cluster 3 was significantly overexpressed in ET patients (accounting for 22.13% of total platelets, compared to 2.94% in the control group), and this subpopulation exhibited higher expression of GPVI and CD63.
- Although cluster 8 was less prevalent in ET patients (1.20%), this subpopulation showed significant upregulation of key receptors in the platelet activation pathway, including PAR1, GPVI, CD69, and activation marker CD62P.

3. **Correlation Between Platelet Count and Mean Platelet Volume (MPV)**:
- Platelet count in ET patients was significantly higher than in the control group, while MPV was significantly lower.
- In ET patients, there was a significant negative correlation between platelet count and MPV, a relationship not observed in the healthy control group.

### Conclusion

The findings of this study indicate that platelets in ET patients are in a highly activated state even at rest, and specific subpopulations exhibit a stronger pro-thrombotic capacity. The high expression of the collagen receptor GPVI, in particular, may be a potential drug target for preventing thrombosis in ET patients. These discoveries provide important clues for further understanding the pathophysiological mechanisms of ET and may serve as a basis for developing new therapeutic strategies.